Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.53 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 16/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743816 | 0.85 | MAP3K14 (0.47) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL1613203 | 0.81 | MAP3K14 (0.67) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL1613145 | 0.79 | MAP3K14 (0.64) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL1614133 | 0.79 | MAP3K14 (0.51) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL12742667 | 0.73 | PIKFYVE (0.72) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL12742758 | 0.72 | PIKFYVE (0.68) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL1613543 | 0.70 | PDK1 (0.55) | MAP3K14PIKFYVECDK5CDK5R1 | |
| SCHEMBL12743305 | 0.70 | MAP3K14 (0.60) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL12743781 | 0.70 | MAP3K14 (0.60) | MAP3K14PIKFYVECLK1CDK5CDK5R1 | |
| SCHEMBL12743817 | 0.69 | MAP3K14 (0.59) | MAP3K14PIKFYVECLK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885PIKFYVE 126/4885CLK1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.